---

Education:

• B.S. North Dakota State University
• Pharm.D. University of Kentucky
• Residency University of Kentucky

Overview

Dr. Johnson joined the U.W.-Madison faculty in 1978. His practice specialty is nephrology. He currently teaches kidney disease-related topics in pharmacotherapy. He also is assisting in the development of international health activities for pharmacy and other health science students at UW-Madison. He holds memberships in many pharmacy and nephrology professional organizations. He serves as a member of the CMS End-Stage Renal Disease Quality Improvement Committee. Dr. Johnson is the editor of the Journal of the Pharmacy Society of Wisconsin.

Work-Related Interests/Research:

Pharmacotherapy of renal diseases

Highlighted Publications:

• Bailie GR, Johnson CA, Mason NA. Parenteral iron products for anemia in end-stage renal disease: Comparative considerations. Formulary 2000; 35:498-513 .
• McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients. Results from the 1998 End-Stage Renal Disease Core Indicators Project. Am J Kidney Dis. 2001; 37:E36.
• Frankenfield DL, Johnson CA. Current management of anemia in adult hemodialysis patients with end-stage renal disease. Am J Health-System Pharm. 2002;59:429-435.
• Coladonato JA, Frankenfield DL. Reddan D, Klassen P, Szezech L, Johnson CA, Owen WF. Trends in anemia management among U.S. hemodialysis patients. J Am Soc Nephrol. 2002;13:1288-1295.
• Johnson CA, McCarthy J, Bailie GR, Deane J, Smith S. Analysis of renal bone disease treatment in dialysis patients. Am J Kidney Dis. 2002;39:1270-7.